Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN
Supernus Pharmaceuticals — Q3 2026 Earnings Presentation
7 slides from Supernus Pharmaceuticals's earnings presentation, Oct 29, 2026
Slide 1: Supernus Announces Third Quarter 2026 Financial Results
Supernus Announces Third Quarter 2026 Financial Results October 29, 2026 Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $192.2 million in the third quarter 2026
Slide 2: Strategic Merger with Indivior and Financial Highlights
Strategic Merger with Indivior Pharmaceuticals, Inc On August 3, 2026, Supernus announced that it had entered into an agreement to combine in an all-stock merger with Indivior. The combination will create a diversified CNS biopharmaceutical leader with significant scale and financial resources to ac
Slide 3: Full Year 2026 Guidance and Non-GAAP Financial Information
(as of October 29, 2026) (as of August 4, 2026) Total revenues include the following(7): ONAPGO net sales of $60 million - $65 million Trokendi XR and Oxtellar XR net sales of $60 million - $67 million $875 - $900 $860 - $890 Operating Earnings (Loss) - GAAP $(5) - $(40) $(20) - $(50) Operating Earn
Slide 4: Forward-Looking Statements
identify forward-looking statements, although not all forward-looking statements contain these words. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks
Slide 5: Condensed Consolidated Balance Sheet
Current liabilities Accounts payable and accrued liabilities $ 109,136 $ 107,800 Accrued product returns and rebates 165,348 161,097 Contingent consideration, current portion — 31,052 Other current liabilities 10,913 38,222 Total current liabilities 285,397 338,171 Contingent consideration, long-ter
Slide 6: Reconciliations of GAAP to Non-GAAP Financial Information
Weighted average shares outstanding Basic 58,202,474 56,552,741 57,975,499 56,133,918 Diluted 59,471,021 56,552,741 57,975,499 56,133,918 (a) Excludes amortization of intangible assets. Supernus Pharmaceuticals, Inc. Reconciliations of GAAP to Non-GAAP Financial Information (unaudited) Reconciliatio
Slide 7: Reconciliation of Full Year 2026 Guidance and Contacts
expense, change in fair value of contingent consideration, depreciation, and intangible asset impairment charges. Reconciliation of Full Year 2026 Financial Guidance - GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings An itemized reconciliation between projected operating earnin
Supernus Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix